THANK YOU FOR SUBSCRIBING
Ongoing research and technological advancements will continue to expand the possibilities of personalised medicine, ultimately improving the lives of cancer patients across Europe and beyond.
FREMONT, CA: The landscape of cancer treatment is experiencing a profound transformation, driven by advancements in genetic research and technology. Previously regarded as a single disease, cancer is now recognised as a complex collection of distinct diseases, each with its unique genetic fingerprint. This insight has led to personalised medicine, an approach that customises treatment based on the specific genetic makeup of a patient's tumour.
Understanding the Genetic Basis of Cancer
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Cancer arises from genetic alterations within a cell's DNA, leading to uncontrolled growth and division. These genetic changes, or mutations, can be inherited from one's parents (germline mutations) or acquired during an individual’s lifetime (somatic mutations). Germline mutations are present in every cell of the body and can elevate the risk of developing specific cancers, such as breast, ovarian, and colon cancer. In contrast, somatic mutations occur in individual cells after birth and are not passed on to offspring. They are responsible for most cancers and contribute to tumour growth and progression.
The Power of Genetic Testing
Genetic testing has become a crucial tool in cancer care. By analysing tumour DNA, doctors can identify genetic alterations that drive cancer growth, which is essential for selecting the most effective treatment options. Tumor profiling, which involves comprehensive genetic analysis, can reveal the type of cancer, its aggressiveness, and potential vulnerabilities. Genetic markers can also predict how a patient will respond to specific therapies, allowing for the avoidance of ineffective treatments and minimising side effects. Additionally, genetic testing can identify individuals with an increased risk of developing cancer due to inherited mutations, enabling early detection and preventive measures that can significantly improve outcomes.
Personalised Medicine: Tailoring Treatment to the Individual
Personalised or precision medicine leverages genetic information to develop customised treatment plans. This approach offers several benefits. By targeting the specific genetic drivers of a tumour, treatments are more likely to be effective, leading to better outcomes. Personalised medicine also reduces side effects by minimising unnecessary therapies and allows for the developing of new therapeutic options by identifying novel genetic targets.
Europe at the Forefront of Personalized Medicine
Europe has emerged as a global leader in personalised medicine research and implementation. This success is attributed to several factors, including a robust research infrastructure, extensive collaboration among researchers, clinicians, and industry, and the early adoption of guidelines for genetic testing and personalised medicine. Notable examples include the United Kingdom’s 100,000 Genomes Project, which has sequenced the genomes of patients with rare diseases and cancer, and Germany’s robust network of cancer centres and research institutions driving advancements in immunotherapy and targeted therapies. France has also made significant investments in genomic medicine, supporting research and the development of personalised treatment plans.
The integration of genetics into oncology is transforming cancer care. By analysing the unique genetic profile of each patient's tumour, physicians can develop highly targeted and effective treatment plans. Europe's strong commitment to research and innovation has positioned the region at the forefront of this transformative field, offering new hope to countless cancer patients.
More in News